Chronic depressive disorders are common, accounting for approximately one-third of all cases of depression and posing a major public health problem. In the past, chronic depression has been thought to be treatment-resistant, and evidence suggests that it is currently underdiagnosed, misdiagnosed, and suboptimally treated.
Objectives:
To review the subtypes of chronic depression and the evidence-base concerning their optimal treatment and to discuss some key clinical issues and areas of future research.
Methods:
We identified key studies and randomized controlled trials (RCTs) by systematically searching electronic databases and hand searching specialist journals and bibliographies.
Results:
Chronic depressive disorders respond well to standard pharmacologic interventions in the acute and maintenance phases of treatment. Standard psychotherapies alone may not be efficacious for chronic depression (especially dysthymia). Recent evidence suggests that treatment combining psychotherapy and medications may be superior to either treatment alone.
Conclusions:
Chronic depressive disorders are amenable to treatment, provided that intervention is both thorough and intensive. Although our knowledge about the optimal treatment of chronic depression has developed rapidly, changes in clinical practice have been slower to evolve. Further research is required to assess the effectiveness of multimodal interventions for chronic depression in more naturalistic settings.
KellerMBLavoriPWMuellerTIEndicottJCoryellWHirschfeldRM, and others. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry1992;49:809–16.
2.
MuellerTIKellerMBLeonACSolomonDASheaMTCoryellW, and others. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry1996;53:794–9.
3.
KellerMBKlermanGLLavoriPWCoryellWEndicottJTaylorJ.Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA1984252:788–92.
4.
WeissmanMMLeafPJBruceMLFlorioL.The epidemiology of dysthymia in five communities: Rates, risks, comorbidity, and treatment. Am J Psychiatry1988;145:815–9.
5.
KesslerRCMcGonagleKAZhaoSNelsonCBHughesMEshlemanS, and others. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry1994;51:8–19.
6.
MarkowitzJCMoranMEKocsisJHFrancesAJ. Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord1992;24:63–71.
7.
LevittAJJoffeRTMacDonaldC.Life course of depressive illness and characteristics of current episode in patients with double depression. J Nerv Ment Dis1991;179:678–82.
8.
KellerMBKleinDNHirschfeldRMKocsisJHMcCulloughJPMillerI, and others. Results of the DSM-IV mood disorders field trial. Am J Psychiatry1995;152:843–9.
9.
WellsKBStewartAHaysRDBurnamMARogersWDanielsM, and others. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA1989;262:914–9.
10.
WellsKBBurnamMARogersWHaysRCampP.The course of depression in adult outpatients. Results from the Medical Outcomes Study. Arch Gen Psychiatry1992;49:788–94.
11.
HaysRDWellsKBSherbourneCDRogersWSpritzerK.Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry1995;52:11–9.
12.
FriedmanRAMarkowitzJCParidesMKocsisJH. Acute response of social functioning in dysthymic patients with desipramine. J Affect Disord1995;34:85–8.
13.
BerndtERKoranLMFinkelsteinSNGelenbergAJKornsteinSGMillerIM, and others. Lost human capital from early-onset chronic depression. Am J Psychiatry2000;157:940–7.
14.
KeitnerGIMillerIW. Family functioning and major depression: An overview. Am J Psychiatry1990;147:1128–37.
15.
MillerIWKeitnerGIWhismanMARyanCEEpsteinNBBishopDS. Depressed patients with dysfunctional families: Description and course of illness. J Abnorm Psychol1992;101:637–46.
16.
Von KorffMOrmelJKatonWLinEH. Disability and depression among high utilizers of health care. A longitudinal analysis. Arch Gen Psychiatry1992;49:91–100.
17.
HowlandRH. Chronic depression. Hospital and Community Psychiatry1993;44:633–9.
18.
KleinDNNordenKAFerroTLeaderJBKaschKLKleinLM, and others. Thirty-month naturalistic follow-up study of early-onset dysthymic disorder: Course, diagnostic stability, and prediction of outcome. J Abnorm Psychol1998;107:338–48.
19.
DavidsonJRMeltzer-BrodySE. The underrecognition and undertreatment of depression: What is the breadth and depth of the problem?J Clin Psychiatry1999;60 (Suppl 9).
20.
KocsisJHFrancesAJVossCMannJJMasonBJSweeneyJ.Imipramine treatment for chronic depression. Arch Gen Psychiatry1988;45:253–7.
21.
KellerMBGelenbergAJHirschfeldRMRushAJThaseMEKocsisJH, and others. The treatment of chronic depression, part 2: A double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry1998;59:598–607.
22.
KellerMBLavoriPW. Double depression, major depression, and dysthymia: Distinct entities or different phases of a single disorder?Psychopharmacol Bull1984;20:399–402.
23.
JuddLLAkiskalHSMaserJDZellerPJEndicottJCoryellW, and others. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord1998;50:97–108.
24.
JuddLLPaulusMJSchettlerPJAkiskalHSEndicottJLeonAC, and others. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?Am J Psychiatry2000;157:1501–4.
25.
RushAJTrivediMH. Treating depression to remission. Psychiatric Annals1995; 25:704–5.
26.
ThaseME. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. American Journal of Managed Care2001;7:S377–S385.
27.
McCulloughJPJrKleinDNKellerMBHolzerCEIIIDavisSMKornsteinSG, and others. Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): Validity of the distinction. J Abnorm Psychol2000;109:419–427.
28.
KocsisJHFriedmanRAMarkowitzJCLeonACMillerNLGniweschL, and others. Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry1996;53:769–74.
29.
de LimaMSHotophMWesselyS.The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis. Psychol Med1999;29:1273–89.
30.
LimaMSMoncrieffJ.A comparison of drugs versus placebo for the treatment of dysthymia. Cochrane Database Syst Rev2000; CD001130.
31.
BakishDLapierreYDWeinsteinRKleinJWiensAJonesB, and others. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol1993;13:409–14.
32.
HellersteinDJYanowitchPRosenthalJSamstagLWMaurerMKaschK, and others. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry1993;150:1169–75.
33.
ThaseMEFavaMHalbreichUKocsisJHKoranLDavidsonJ, and others. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry1996;53:777–84.
34.
RavindranAVGuelfiJDLaneRMCassanoGB. Treatment of dysthymia with sertraline: A double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry2000;61:821–7.
35.
VallejoJGastoCCatalanRSalameroM.Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry1987;151:639–42.
36.
GuelfiJDPichotPDreyfusJF. Efficacy of tianeptine in anxious-depressed patients: Results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology1989;22:41–8.
37.
StewartJWMcGrathPJQuitkinFMHarrisonWMarkowitzJWagerS, and others. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry1989;46:1080–7.
38.
BersaniGPozziFMariniSGrispiniAPasiniACianiN.5-HT2 receptor antagonism in dysthymic disorder: A double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand1991;83:244–8.
39.
NierenbergAADeCeccoLM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry2001;62 Suppl 16:5–9.
40.
JoffeRSokolovSStreinerD.Antidepressant treatment of depression: A meta-analysis. Can J Psychiatry1996;41:613–6.
41.
MulrowCDWilliamsJWJrChiquetteEAguilarCHitchcock-NoelPLeeS, and others. Efficacy of newer medications for treating depression in primary care patients. Am J Med2000;108:54–64.
42.
MillerIWKeitnerGISchatzbergAFKleinDNThaseMERushAJ, and others. The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry1998;59:608–19.
43.
FinkelsteinSNBerndtERGreenbergPEParsleyRARussellJMKellerMB. Improvement in subjective work performance after treatment of chronic depression: Some preliminary results. Chronic Depression Study Group. Psychopharmacol Bull1996;32:33–40.
44.
KoranLMGelenbergAJKornsteinSGHowlandRHFriedmanRADebattistaC, and others. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord2001;65:27–36.
45.
ScottJ.Cognitive therapy of affective disorders: A review. J Affect Disord1996;37:1–11.
46.
HirschfeldRMMontgomerySAKellerMBKasperSSchatzbergAFMollerHJ, and others. Social functioning in depression: A review. J Clin Psychiatry2000;61:268–75.
47.
ScottJ.Where there's a will: Cognitive therapy for people with chronic depressive disorders. In: TarrierNWellsAHaddockG, editors. Treating complex cases: The cognitive behavioural therapy approach. Chichester (UK): John Wiley; 1998. p 81–104.
48.
MasonBJMarkowitzJKlermanGL. IPT for dysthymic disorder. In: KlermanGLWeissmanMM, editors. New applications of interpersonal therapy.Washington (DC): American Psychiatric Press; 1993. p 225–64.
49.
MarkowitzJC. Psychotherapy for dysthymic disorder. Psychiatr Clin North Am1996;19:133–49.
50.
SimpsonSCorneyRFitzgeraldPBeechamJ.A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression. Health Technol Assess2000;4:1–83.
51.
BarrettJEWilliamsJWJrOxmanTEFrankEKatonWSullivanM, and others. Treatment of dysthymia and minor depression in primary care: A randomized trial in patients aged 18 to 59 years. J Fam Pract2001;50:405–12.
52.
WilliamsJWJrBarrettJOxmanTFrankEKatonWSullivanM, and others. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA2000;284:1519–26.
53.
ThaseMEReynoldsCFIIIFrankESimonsADMcGearyJFasiczkaAL, and others. Do depressed men and women respond similarly to cognitive behavior therapy?Am J Psychiatry1994;151:500–5.
54.
SegalZVWhitneyDKLamRW. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry2001;46 Suppl 1:29S–37S.
55.
WaringEMChamberlaineCHMcCrankEWStalkerCACarverCFryR, and others. Dysthymia: A randomized study of cognitive marital therapy and antidepressants. Can J Psychiatry1988;33:96–9.
56.
RavindranAVAnismanHMeraliZCharbonneauYTelnerJBialikRJ, and others. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. Am J Psychiatry1999;156:1608–17.
57.
HellersteinDJLittleSASamstagLWBatchelderSMuranJCFedakM, and others. Adding group psychotherapy to medication treatment in dysthymia: A randomized prospective pilot study. J Psychother Pract Res2001;10:93–103.
58.
KellerMBMcCulloughJPKleinDNArnowBDunnerDLGelenbergAJ, and others. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med2000;342:1462–70.
59.
McCulloughJP. Cognitive behavioural analysis system of psychotherapy. New York, NY. Guilford. 2000.
60.
HirschfeldRMDunnerDLKeitnerGI. Treatment of psychosocial impairments in major depression. New Research Abstracts.Chicago: American Psychiatric Association; 2000. Abstract NR461:183.
61.
RubinRT. Nefazodone, psychotherapy, and their combination for chronic depression. N Engl J Med2000;343:1041–3.
62.
KhanADagerSRCohenSAveryDHScherzoBDunnerDL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology1991;4:125–30.
63.
TrivediMHRushH.Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?Neuropsychopharmacology1994;11:33–43.
64.
BrownGSteinerMRobertsJGafniAByrneCDunnE, and others. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord2002;68:317–30.
65.
SegalZVWhitneyDKLamRW. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry2001;46 Suppl 1:29S–37S.
66.
KellerMBSessaFM. Dysthymia: Development and clinical course. In: AkiskalHSBurtonSW, editors. Dysthymic disorder.London (UK): Gaskell Publications; 1993.
67.
RussellJMKoranLMRushJHirschfeldRMHarrisonWFriedmanES, and others. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety2001;13:18–27.
68.
PattenSB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord2001;63:35–41.
69.
KeitnerGIRyanCEMillerIWKohnREpsteinNB. 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry1991;148:345–50.
70.
EnnsMWSwensonJRMcIntyreRSSwinsonRPKennedySH. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry2001;46 Suppl 1:77S–90S.
ThaseME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry2001;62:221–4.
73.
RushAJThaseME. Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry1997;58 Suppl 13:14–22.
74.
TrivediMHKleiberBA. Using treatment algorithms for the effective management of treatment-resistant depression. J Clin Psychiatry2001;62 Suppl 18:25–9.
75.
KennedySHLamRWCohenNLRavindranAV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry2001;46 Suppl 1:38S–58S.
76.
ThaseMERushAJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry1997;58 Suppl 13:23–9.
77.
RushAJThaseME. Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry1997;58 Suppl 13:14–22.
78.
AgostiVStewartJWQuitkinFM. Life satisfaction and psychosocial functioning in chronic depression: Effect of acute treatment with antidepressants. J Affect Disord1991;23:35–41.
79.
DevereauxECarlsonM.The role of occupational therapy in the management of depression. Am J Occup Ther1992;46:175–80.
80.
KellerMBLavoriPWLewisCEKlermanGL. Predictors of relapse in major depressive disorder. JAMA1983;250:3299–3304.
81.
FrankEKupferDJPerelJMCornesCJarrettDBMallingerAGThaseMEMcEachranABGrochocinskiVJ. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry1990;47:1093–9.
82.
MelfiCAChawlaAJCroghanTWHannaMPKennedySSredlK.The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry1998;55:1128–32.
83.
RamanaRPaykelESSurteesPGMelzerDMehtaMA. Medication received by patients with depression following the acute episode: Adequacy and relation to outcome. Br J Psychiatry1999;174:128–34.
84.
CoulterA.Partnerships with patients: The pros and cons of shared clinical decision-making. Journal of Health Services Research and Policy1997;2:112–21.
85.
FrankEKupferDJWagnerEFMcEachranABCornesC.Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors. Arch Gen Psychiatry1991;48:1053–9.
86.
JarrettRBKraftDDoyleJFosterBMEavesGGSilverPC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: A randomized clinical trial. Arch Gen Psychiatry2001;58:381–8.
87.
AkiskalHSRosenthalTLHaykalRFLemmiHRosenthalRHScott-StraussA.Characterological depressions. Clinical and sleep EEG findings separating ‘subaffective dysthymias’ from ‘character spectrum disorders’. Arch Gen Psychiatry1980;37:777–83.
88.
KocsisJHFrancesAJ. A critical discussion of DSM-III dysthymic disorder. Am J Psychiatry1987;144:1534–42.
